CANCER:

Neuroendocrine Tumor

No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	surufatinib Sensitive: A1 - Approval
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	sunitinib Sensitive: A1 - Approval
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	everolimus Sensitive: A1 - Approval
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	lanreotide prolonged-release subcutaneous Sensitive: A1 - Approval
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	sunitinib Sensitive: A1 - Approval
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	EP Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	octreotide Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	temozolomide Sensitive: A2 - Guideline
SSTR positive SSTR positive	Neuroendocrine Tumor Neuroendocrine Tumor	lanreotide prolonged-release subcutaneous Sensitive: A2 - Guideline
SSTR positive SSTR positive	Neuroendocrine Tumor Neuroendocrine Tumor	octreotide Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	FOLFOX Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	carboplatin + etoposide IV Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	temozolomide + capecitabine Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Neuroendocrine Tumor Neuroendocrine Tumor	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	oxaliplatin Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	dacarbazine Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	cisplatin + etoposide IV Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	5-fluorouracil Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	capecitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	nivolumab + ipilimumab Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	FOLFIRINOX Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	carboplatin + irinotecan Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	cisplatin + irinotecan Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	FOLFIRI Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	CAPOX Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	5-fluorouracil + streptozocin Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	doxorubicin hydrochloride + streptozocin Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	streptozocin Sensitive: A2 - Guideline
TMB-H TMB-H	Neuroendocrine Tumor Neuroendocrine Tumor	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	FAS Sensitive: A2 - Guideline
SSTR positive SSTR positive	Neuroendocrine Tumor Neuroendocrine Tumor	lutetium Lu 177 dotatate Sensitive: B - Late Trials
BRAF V600E BRAF V600E	Neuroendocrine Tumor Neuroendocrine Tumor	trametinib + dabrafenib Sensitive: C1 - Off-label
RET fusion RET fusion	Neuroendocrine Tumor Neuroendocrine Tumor	selpercatinib Sensitive: C1 - Off-label
DLL3 overexpression DLL3 overexpression	Neuroendocrine Tumor Neuroendocrine Tumor	rovalpituzumab tesirine Sensitive: C2 – Inclusion Criteria
SSTR2 positive SSTR2 positive	Neuroendocrine Tumor Neuroendocrine Tumor	PEN-221 Sensitive: C2 – Inclusion Criteria
PD-L1 expression PD-L1 expression	Neuroendocrine Tumor Neuroendocrine Tumor	toripalimab Sensitive: C2 – Inclusion Criteria
PD-L1 expression PD-L1 expression	Neuroendocrine Tumor Neuroendocrine Tumor	PDR001 Sensitive: C3 – Early Trials
mTOR expression + RPS6KB1 expression mTOR expression + RPS6KB1 expression	Neuroendocrine Tumor Neuroendocrine Tumor	everolimus Sensitive: C3 – Early Trials
MGMT deletion MGMT deletion	Neuroendocrine Tumor Neuroendocrine Tumor	temozolomide Sensitive: C3 – Early Trials
TMB-H TMB-H	Neuroendocrine Tumor Neuroendocrine Tumor	toripalimab Sensitive: C3 – Early Trials
FGFR4 G388R FGFR4 G388R	Neuroendocrine Tumor Neuroendocrine Tumor	everolimus Resistant: C3 – Early Trials
CA9 overexpression CA9 overexpression	Neuroendocrine Tumor Neuroendocrine Tumor	doxorubicin hydrochloride Resistant: C3 – Early Trials
FLT4 T494A FLT4 T494A	Neuroendocrine Tumor Neuroendocrine Tumor	pazopanib Resistant: C3 – Early Trials
FLT4 R1324L FLT4 R1324L	Neuroendocrine Tumor Neuroendocrine Tumor	pazopanib Resistant: C3 – Early Trials
VHL mutation VHL mutation	Neuroendocrine Tumor Neuroendocrine Tumor	PT2385 Sensitive: C3 – Early Trials
TP53 mutation TP53 mutation	Neuroendocrine Tumor Neuroendocrine Tumor	pazopanib Sensitive: C3 – Early Trials
SSTR5 expression SSTR5 expression	Neuroendocrine Tumor Neuroendocrine Tumor	octreotide Sensitive: C3 – Early Trials
SSTR2 expression SSTR2 expression	Neuroendocrine Tumor Neuroendocrine Tumor	octreotide Sensitive: C3 – Early Trials
SSTR Expression SSTR Expression	Neuroendocrine Tumor Neuroendocrine Tumor	212Pb-labeled peptide Sensitive: C3 – Early Trials
MSI-H/dMMR + PD-L1 expression MSI-H/dMMR + PD-L1 expression	Neuroendocrine Tumor Neuroendocrine Tumor	Immunotherapy Sensitive: C3 – Early Trials
VHL mutation VHL mutation	Neuroendocrine Tumor Neuroendocrine Tumor	MK-6482 Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Neuroendocrine Tumor Neuroendocrine Tumor	toripalimab Sensitive: C3 – Early Trials
TMB-L TMB-L	Neuroendocrine Tumor Neuroendocrine Tumor	toripalimab Sensitive: C3 – Early Trials
EWSR1-CREB1 fusion EWSR1-CREB1 fusion	Neuroendocrine Tumor Neuroendocrine Tumor	crizotinib + pazopanib Sensitive: C4 – Case Studies
MUC16 elevation MUC16 elevation	Neuroendocrine Tumor Neuroendocrine Tumor	TC Sensitive: C4 – Case Studies
TMB-L + PD-L1 expression TMB-L + PD-L1 expression	Neuroendocrine Tumor Neuroendocrine Tumor	nivolumab + ipilimumab Sensitive: C4 – Case Studies
BRAF V600E BRAF V600E	Neuroendocrine Tumor Neuroendocrine Tumor	pazopanib Resistant: C4 – Case Studies
BRAF V600E BRAF V600E	Neuroendocrine Tumor Neuroendocrine Tumor	trametinib + vemurafenib Sensitive: C4 – Case Studies
BRCA2 exon 11 deletion BRCA2 exon 11 deletion	Neuroendocrine Tumor Neuroendocrine Tumor	olaparib Resistant: C4 – Case Studies
ETV6-NTRK3 fusion ETV6-NTRK3 fusion	Neuroendocrine Tumor Neuroendocrine Tumor	entrectinib Sensitive: C4 – Case Studies
CEACAM5 expression CEACAM5 expression	Neuroendocrine Tumor Neuroendocrine Tumor	IMMU-130 Sensitive: D – Preclinical
TYRO3 mutation + ALK mutation TYRO3 mutation + ALK mutation	Neuroendocrine Tumor Neuroendocrine Tumor	sunitinib Sensitive: D – Preclinical
TYRO3 mutation + ALK mutation TYRO3 mutation + ALK mutation	Neuroendocrine Tumor Neuroendocrine Tumor	crizotinib + sunitinib Sensitive: D – Preclinical
TYRO3 mutation + ALK mutation TYRO3 mutation + ALK mutation	Neuroendocrine Tumor Neuroendocrine Tumor	crizotinib Resistant: D – Preclinical

Neuroendocrine Tumor

Associations(65)

Associations
(65)